Delta commits to breast cancer research with a new global funding approach and expanded employee and customer programs

Delta Air Lines is expanding its breast cancer research partnership with the Breast Cancer Research Foundation, saying the effort has generated $36 million over more than two decades and funded research hours that have reached more than 720,000. The airline, which is treating the initiative as part of its October Breast Cancer Awareness Month push, says 2026 will bring a new global approach to research funding as well as additional ways for employees and customers to learn, give, and show support.

In remarks included with the company announcement, Kristen Manion Taylor, Delta’s senior vice president of brand experience, said the disease is personal for many in the Delta community and that the company wants to deepen its support for BCRF as it looks ahead. Delta framed the partnership as both a funding effort and a community engagement program, built to connect customers, employees, and researchers around the goal of improving outcomes after diagnosis.

Delta also highlighted one specific research effort tied to its funding. It pointed to the OPTIMA trial, which the company said examines whether some patients with high-risk breast cancer might be able to safely forgo chemotherapy. Delta said the trial builds on a genomic test developed through research supported by BCRF, and that it is intended to help advance a more personalized approach to treatment by identifying patients who may benefit from chemotherapy.

The airline’s announcement ties the funding and research support to an estimate for the scale of the problem in the United States, saying that in 2026 an estimated 324,580 people will be diagnosed with breast cancer. It also said that beyond the statistics, the research timeline matters because discoveries often follow years of work before they translate into options for patients and clinicians.

A central element of Delta’s updated approach is the creation of The Delta Air Lines Fund in Support of Global Breast Cancer Research. Delta said the fund broadens the company’s funding beyond individual researchers by bringing donations made through the Team Delta donation page together under the Delta Fund name, with the intent of broadening opportunities for scientists worldwide and fostering collaboration and data-driven discoveries across borders.

Delta positioned the new fund alongside BCRF’s leadership perspective. In the company release, Donna McKay, president and chief executive officer of BCRF, said Delta’s support helped make progress possible and that the foundation is excited to build on momentum by creating new opportunities for researchers around the world. The announcement did not offer additional performance metrics beyond the cumulative figures Delta cited for the broader partnership.

For employees, Delta said it continues to support outreach and prevention options through its benefit and health programs. It stated that in-network mammograms are covered at no additional cost through Delta medical plans, and that onsite mobile mammography appointments are available at Delta locations in Atlanta and Minneapolis. It also referenced a cancer support group called Hope Thrives for employees affected by cancer.

Delta’s internal community program is also moving into a new iteration of its Breast Cancer One (BC1) Charter, which it described as a group for Delta employees impacted by breast cancer that provides connection, recognition, and community. The company said the 2026 charter will fly Oct. 7 to 9 from Atlanta (ATL) to Las Vegas (LAS), and it listed activities including a welcome celebration, conversations with BCRF researchers, and a private F1 Arcade experience. Delta said creator and breast cancer survivor Bridget Bahl will join the group to share her experience and connect the effort to awareness, early detection, community, and research.

Delta said the effort extends beyond employee events and includes customer-facing ways to support BCRF during October. It stated that customers can donate directly to BCRF through, and SkyMiles members can donate miles through SkyWish. It also described a public-facing kickoff on the partnership’s work at Grand Central Terminal’s Vanderbilt Hall, where an interactive experience covered prevention and life after diagnosis, along with opportunities to give back.

While the announcement provides specific figures and program details, it does not disclose the size of new donation commitments for the 2026 period or how the expanded global funding approach will change allocation decisions from year to year. Delta also did not provide independent outcome data from any particular research program, beyond describing the purpose of the OPTIMA trial and its link to a genomic test.

Looking ahead, the key indicates to watch are how Delta’s new Delta Air Lines Fund is administered and how it affects the mix of researchers and study types supported through BCRF. In the near term, the October employee charter, additional prevention support offerings, and customer donation pathways may also serve as indicators of how the airline plans to sustain engagement across its customer base and workforce. For breast cancer research stakeholders, the more immediate question is whether initiatives like OPTIMA continue to move toward treatment options that reduce reliance on chemotherapy for the patients most likely to be eligible, based on the genomic approach described by Delta.